CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
Rotarix TMbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01198769
NCT01198769Phase 4Completed
CompareCT.gov

Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

GlaxoSmithKline·interventional·Posted Sep 10, 2010·Updated Aug 20, 2018

In Brief

A Phase 4 clinical trial evaluating Rotarix TM for Infections, Rotavirus. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to assess immunogenicity and safety of Rotarix TM when administered in healthy Taiwanese infants (aged 6 to 12 weeks at the time of first vaccination) who received Hepatitis B immunoglobulin after birth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Rotavirus
CountriesTaiwan
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2010
Enrollment StartNov 11, 2010
Primary CompletionApr 18, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.8 years ago

Interventions

Rotarix TMbiological

Oral, 2 doses